12 active not recruiting. 12 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 12 |
| Phase 1 | 6 | Active not recruiting 6 |
Follow Anemia, Aplastic: new trials by email Literature Review of Anemia, Aplastic trials Research Report on Anemia, Aplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure Ruxolitinib - Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 13 | 2024-02-20 | 2026-10-14 |
| Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant Abatacept - Graft Versus Host Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2019-08-22 | 2026-02-25 |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2019-08-08 | 2026-06-11 |
| Eltrombopag for Fanconi Anemia Eltrombopag - Fanconi Anemia | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 25 | 2018-11-02 | 2026-09-16 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Sirolimus - Severe Aplastic Anemia | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 84 | 2016-12-19 | 2026-10-06 |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation CD34 Stem Cell Selection Therapy - Bone Marrow Failure Syndrome, Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | Diane George | 37 | 2013-03-01 | 2025-08-14 |
| Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 - Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 207 | 2012-07-02 | 2026-04-13 |
| Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita alemtuzumab, Fludarabine, Cyclosporins - Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome | Phase 2 | Active not recruiting | Boston Children's Hospital | 40 | 2012-07-01 | 2026-03-27 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders busulfan, cyclophosphamide, cyclosporine - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Active not recruiting | City of Hope Medical Center | 260 | 2001-10-16 | 2026-06-02 |
Lymphoma, Non-Hodgkin (4) · Myelodysplastic Syndromes (4) · Bone Marrow Failure Disorders (3) · Graft vs Host Disease (3) · Hodgkin Disease (3) · Leukemia, Myeloid, Acute (3) · Multiple Myeloma (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Sickle Cell (2) · Fanconi Anemia (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)
Anemia (12) · Bone Marrow Diseases (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Bone Marrow Failure Disorders (9) · Immune System Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Congenital Bone Marrow Failure Syndromes (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4)
Cyclosporine (4) · Mycophenolic Acid (4) · Sirolimus (4) · Whole-Body Irradiation (4) · Cyclophosphamide (3) · Peripheral Blood Stem Cell Transplantation (3) · fludarabine (3) · fludarabine phosphate (3) · Cyclosporins (2) · Melphalan (2) · Tacrolimus (2) · eltrombopag (2) · ruxolitinib (2) · AP 1903 reagent (1) · Abatacept (1)
National Heart, Lung, and Blood Institute (NHLBI) (4) · Bellicum Pharmaceuticals (1) · Boston Children's Hospital (1) · City of Hope Medical Center (1) · Diane George (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (11) · Norway (1) · Sweden (1)
Andre Larochelle, M.D. (1) · Auayporn P. Nademanee, MD (1) · Bhavisha A Patel, M.D. (1) · Bhavisha Patel, M.D. (1) · Diane George, MD (1) · John Horan, MD (1) · Maureen Ross (1) · Neal S Young, M.D. (1) · Rachel B. Salit, MD (1) · Richard E Champlin (1) · Suneet Agarwal, MD, PHD (1)
PMID 26354756, PMID 29419434, PMID 29674506, PMID 29958797, PMID 33410523, PMID 33910334, PMID 34086408, PMID 34525188, PMID 34724566
P30CA033572 (1)